SILONasdaqPharmaceutical PreparationsFiscal year ends December 31
Silo Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.13−0.05 (-4.24%)
Close on Oct 19, 2026
- Market cap
- $1.24M
- P/E (TTM)
- –
- Dividend yield
- –
Silo Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Market Cap | $1.79M | $197.05M |
| Enterprise Value | -$3.43M | $106.56M |
| PS Ratio | 33.19 | 3.93 |
| PB Ratio | 0.37 | 2.14 |
| P/TBV Ratio | 0.38 | 2.46 |
Enterprise value
| Measure | Silo Pharma | Industry median |
|---|---|---|
| EV / Sales | -63.47 | 2.69 |
Income (trailing twelve months)
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Revenue | $54.08K | $57.94M |
| Gross Profit | -$7.99K | $90.47M |
| Operating Income | -$4.46M | -$21.44M |
| Pretax Income | -$4.47M | -$14.45M |
| Net Income | -$4.47M | -$22.46M |
| EBITDA | -$4.46M | -$16.91M |
Margins
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Gross Margin | -14.8% | 52.3% |
| Operating Margin | -8250.5% | -44.5% |
| Pretax Margin | -8269.5% | -13.0% |
| Profit Margin | -8269.5% | -39.2% |
| EBITDA Margin | -8250.5% | -31.3% |
Returns
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -91.2% | -53.1% |
| Return on Assets (ROA) | -71.0% | -41.0% |
| Return on Capital Employed (ROCE) | -91.3% | -37.8% |
Growth
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -25.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 0.00% | 2.25% |
| Revenue Growth (5Y CAGR) | 12.0% | 6.42% |
Balance sheet
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $5.23M | $62.42M |
| Net Cash (Debt) | $5.23M | $15.68M |
| Net Cash Per Share | $3.29 | $0.65 |
| Equity (Book Value) | $4.89M | $48.79M |
| Book Value Per Share | $3.08 | $1.36 |
| Tangible Book Value | $4.67M | $23.06M |
| Working Capital | $4.65M | $75.77M |
Financial position
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Current Ratio | 5.36 | 3.30 |
| Quick Ratio | 4.90 | 2.39 |
| Interest Coverage | -112.03 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.34M | -$12.35M |
Efficiency
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $18.03K | $398.96K |
| Profits Per Employee | -$1.49M | -$732.08K |
| Employee Count | 3 | 73 |
Dividends and yields
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Earnings Yield | -249.2% | -21.2% |
Shares
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 1,588,250 | 59,128,900 |
| Shares Change (YoY) | 170.5% | 11.1% |
| Shares Change (QoQ) | 4.07% | 0.54% |
| Float | 1,368,820 | 48,744,500 |
| Shares Held by Insiders | 13.8% | 11.8% |
| Shares Held by Institutions | 9.00% | 59.4% |
Scores
| Measure | Silo Pharma | Industry median |
|---|---|---|
| Altman Z-Score | -5.69 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Silo Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.